Ginisortamab

DB18863InvestigationalProtein Based Therapies

Ginisortamab is under investigation in clinical trial NCT04393298 (A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors).

Mechanism: Pharmacologically active on Gremlin-1
Curator reviewed
Also known as: Immunoglobulin g4 (232-proline), anti-(human gremlin 1) (human monoclonal ucb6114 .gamma.4-chain), disulfide with human monoclonal ucb6114 .kappa.-chain, dimer
Code names: UCB-6114

Resolves to

Compound

UNII6808SG2XRKCAS2390147-17-6

Targets

O60565GREM1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Ginisortamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account